Literature DB >> 1661656

Anti-aggregatory effects of physiological concentrations of adenosine in human whole blood as assessed by filtragometry.

U Söderbäck1, A Sollevi, N H Wallen, P T Larsson, P Hjemdahl.   

Abstract

1. The anti-aggregatory effect of adenosine (0.3-10 mumol/l), alone or in combination with the adenosine-uptake inhibitor dipyridamole (2 mumol/l), was studied in vitro in whole blood from 11 healthy subjects by filtragometry. 2. ADP (0.05-0.1 mumol/l) was used to reduce the filter occlusion time (tA, a measure of platelet aggregate formation in blood) from approximately 600 s to 71-101 s in the absence of other agents. 3. Adenosine was infused into the tubing system of the filtragometer, yielding a contact time of approximately 25 s with the blood before the filter. Adenosine did not influence the aggregatory response to ADP significantly at 0.3 mumol/l in plasma, whereas tA was prolonged by 19 +/- 6% (P less than 0.02) at 1 mumol/l adenosine and by 259 +/- 78% (P less than 0.02) at 3 mumol/l adenosine. 4. When the rapid elimination of adenosine from plasma was prevented by 2 mumol/l dipyridamole, adenosine caused marked prolongation of ADP-induced tA, with significant effects at 0.3 mumol/l (+143 +/- 72%, P less than 0.05). Dipyridamole per se did not affect tA values. 5. The present results suggest that adenosine has a transient anti-aggregatory effect in whole blood at about 0.3 mumol/l, as this is the highest possible calculated concentration of adenosine at the filter of the apparatus when 1 mumol/l adenosine is infused in the absence of dipyridamole or when 0.3 mumol/l adenosine is infused in its presence. 6. It is concluded that adenosine has anti-aggregatory effects at submicromolar (physiological) concentrations in human whole blood.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1661656     DOI: 10.1042/cs0810691

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  6 in total

Review 1.  Adenosine receptors and reperfusion injury of the heart.

Authors:  John P Headrick; Robert D Lasley
Journal:  Handb Exp Pharmacol       Date:  2009

Review 2.  Anti-platelet therapy: phosphodiesterase inhibitors.

Authors:  Paolo Gresele; Stefania Momi; Emanuela Falcinelli
Journal:  Br J Clin Pharmacol       Date:  2011-10       Impact factor: 4.335

3.  Adenosine receptor-induced cyclic AMP generation and inhibition of 5-hydroxytryptamine release in human platelets.

Authors:  J A Cooper; S J Hill; S P Alexander; P C Rubin; E H Horn
Journal:  Br J Clin Pharmacol       Date:  1995-07       Impact factor: 4.335

4.  Adenosine reduces postbypass transfusion requirements in humans after heart surgery.

Authors:  R M Mentzer; P S Rahko; C C Canver; P S Chopra; R B Love; T D Cook; M O Hegge; R D Lasley
Journal:  Ann Surg       Date:  1996-10       Impact factor: 12.969

5.  Low-molecular-weight compounds with anticoagulant activity from the scorpion Heterometrus laoticus venom.

Authors:  Tran Vu Thien; Hoang Ngoc Anh; Nguyen Thi Thuy Trang; Phung Van Trung; Nguyen Cuu Khoa; A V Osipov; P V Dubovskii; I A Ivanov; A S Arseniev; V I Tsetlin; Yu N Utkin
Journal:  Dokl Biochem Biophys       Date:  2017-11-04       Impact factor: 0.788

6.  Anticoagulant Activity of Low-Molecular Weight Compounds from Heterometrus laoticus Scorpion Venom.

Authors:  Thien Vu Tran; Anh Ngoc Hoang; Trang Thuy Thi Nguyen; Trung Van Phung; Khoa Cuu Nguyen; Alexey V Osipov; Igor A Ivanov; Victor I Tsetlin; Yuri N Utkin
Journal:  Toxins (Basel)       Date:  2017-10-26       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.